Disclosed are implants, devices and systems capable of being deployed within the neurovasculature of a subject. The implants are configured for enhanced conformability to a vessel wall and have thromboresistant design features and coatings. The devices for implant deployment are configured for precise placement of an implant, resheathing of a partially deployed implant, and reliable detachment of an implant without distorting the positioning of the implant.

Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.

Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.

A transcatheter pulmonary flow restrictor device comprising a disk-shaped body, which is concave on the proximal side and convex on the distal side, made from tightly interwoven ultra-thin mesh wires with shape memory and no substantial gaps to restrict pulmonary blood flow. The disk-shaped body has two symmetrically positioned openings on opposite sides of the disk center for passage of blood flow. The device may further comprise a central screw on the proximal side, an appendage on the distal side opposite the central screw, a heparin-based bioactive coating over the mesh wires, an antibacterial layer within or over the mesh wires, and two radio-opaque markers associated with the openings for proper positioning of the device. Materials of the device vary based on the intended duration of use in the pulmonary arterial branches, including the use of smart, bioresponsive, and biodegradable materials with an inverse relationship between pulmonary arterial pressure and device degradation.

A transcatheter pulmonary flow restrictor device comprising a disk-shaped body, which is concave on the proximal side and convex on the distal side, made from tightly interwoven ultra-thin mesh wires with shape memory and no substantial gaps to restrict pulmonary blood flow. The disk-shaped body has two symmetrically positioned openings on opposite sides of the disk center for passage of blood flow. The device may further comprise a central screw on the proximal side, an appendage on the distal side opposite the central screw, a heparin-based bioactive coating over the mesh wires, an antibacterial layer within or over the mesh wires, and two radio-opaque markers associated with the openings for proper positioning of the device. Materials of the device vary based on the intended duration of use in the pulmonary arterial branches, including the use of smart, bioresponsive, and biodegradable materials with an inverse relationship between pulmonary arterial pressure and device degradation.

Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including a direct factor Xa inhibitor, and a direct factor IIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent an injury site in the patient's body. The one or more active substances optionally include an anti-proliferative agent. The therapeutic composition is formulated to release the one or more active substances to the injury site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation.

Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including a direct factor Xa inhibitor, and a direct factor IIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent an injury site in the patient's body. The one or more active substances optionally include an anti-proliferative agent. The therapeutic composition is formulated to release the one or more active substances to the injury site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation.

A nanostructured low-immunogenic biological artificial blood vessel, a preparation method therefor and a use thereof. The preparation method comprises: decellularizing a pre-treated animal blood vessel to obtain a decellularized blood vessel; treating the decellularized blood vessel in an enzyme solution to obtain an enzyme-treated blood vessel, wherein the enzyme solution comprises nuclease and/or a biological enzyme; and using a cross-linking agent to cross-link the enzyme-treated blood vessel to obtain a nanostructured low-immunogenic biological artificial blood vessel, which is used as a blood vessel transplantation material. The artificial blood vessel overcomes the defects of decreased mechanical properties in decellularized biological tissues, in-vivo calcification after long-term use, and the presence of immunogenicity, antigenic components such as vascular wall cells and cell nuclei are fully removed, and original collagen and other extracellular matrix structural proteins in the tissue are retained to a greater extent, avoiding the in-vivo calcification of the blood vessel upon long-term implantation, enhancing the durability of use of the blood vessel; and the method has a short preparation cycle, low cost and high long-term patency rate.

A nanostructured low-immunogenic biological artificial blood vessel, a preparation method therefor and a use thereof. The preparation method comprises: decellularizing a pre-treated animal blood vessel to obtain a decellularized blood vessel; treating the decellularized blood vessel in an enzyme solution to obtain an enzyme-treated blood vessel, wherein the enzyme solution comprises nuclease and/or a biological enzyme; and using a cross-linking agent to cross-link the enzyme-treated blood vessel to obtain a nanostructured low-immunogenic biological artificial blood vessel, which is used as a blood vessel transplantation material. The artificial blood vessel overcomes the defects of decreased mechanical properties in decellularized biological tissues, in-vivo calcification after long-term use, and the presence of immunogenicity, antigenic components such as vascular wall cells and cell nuclei are fully removed, and original collagen and other extracellular matrix structural proteins in the tissue are retained to a greater extent, avoiding the in-vivo calcification of the blood vessel upon long-term implantation, enhancing the durability of use of the blood vessel; and the method has a short preparation cycle, low cost and high long-term patency rate.